Although we expect Boston Scientific to post in-line results in Q2, our forecast indicates that BSX stock is undervalued at its current levels, as discussed below. (3) BSX stock appears to be undervalued We estimate Boston Scientific’s Valuation to be $47 per share, which is 27% above the current market price of $37. With inflation rising and the Fed raising interest rates, among other factors, BSX stock has fallen 14% this year.